Details of the Drug Reposition

General Information of This Drug (ID: DM7TZL0)

Drug Name
INCB054329   DM7TZL0
Synonyms
1628607-64-6; (S)-6-(3,5-dimethylisoxazol-4-yl)-3-(pyridin-2-yl)-3,4-dihydro-5-oxa-1,2a-diazaacenaphthylen-2(1H)-one; Q50825078; SCHEMBL16038298; INCB54329; US9624241, Example 14; BDBM318469; INCB-54329; EX-A3126; INCB-054329; NSC816024; s8753; NSC-816024; HY-112504; CS-0046160; INCB054329 pound INCB-054329,INCB-54329 pound(c); CC1=NOC(C)=C1C1=CC=C2C3=C1OC[C@H](C=1N=CC=CC=1)N3C(=O)N2; (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1/2 [1]
Refractory hematologic malignancy DISBBTY5 2A85.5 Phase 1/2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02431260) An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies. U.S. National Institutes of Health.